natgillin/translations-raw huggingface dataset:
Programmet har til forml at skabe et offentlig-privat partnerskab for opdagelse og udvikling af nye antimikrobielle behandlinger og disses markedsadgang. 
This aims to forge a public private partnership for the discovery, development and market entry of new antimicrobial treatments.
Kommissionen finansierer ogs tiltag til at koordinere og fastsžtte en strategisk forskningsdagsorden for AMR, isžr via det fžlles programlžgningsinitiativ om antimikrobiel resistens (JPIAMR). 
The Commission also funds actions to coordinate and set an AMR strategic research agenda, particularly through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR).
Revisionens omfang og revisionsmetoden 18 I betragtning af den stigende trussel fra antimikrobiel resistens, som afspejles i WHO's globale handlingsplan og Kommissionens handlingsplan, undersżgte vi, om Kommissionen og de relevante EU-agenturer forvaltede centrale aktiviteter og ressourcer til stżtte for medlemsstaterne og EU-finansieret forskning med henblik p bekžmpelse af antimikrobiel resistens hensigtsmžssigt. 
Audit scope and approach 18 Given the rising threat of antimicrobial resistance, reflected in the WHO Global Action Plan and the Commission action plan, we examined whether the Commission and relevant EU agencies managed well key activities and resources to support Member States and EU funded research aimed at fighting antimicrobial resistance.
Dette omfattede arbejde, som kan bidrage til den nye ramme for AMR-overvgning og en bedre anvendelse af antimikrobielle stoffer. 
This included work which can contribute to the new AMR monitoring framework and the better use of antimicrobials.
Dette hovedspżrgsml er opdelt i tre underspżrgsml: 1) Har Kommissionen og ECDC forvaltet centrale aktiviteter og ressourcer til stżtte for medlemsstaternes One Health-reaktion p AMR under EU's handlingsplan hensigtsmžssigt? 
This main objective is broken down into three sub-questions: (1) Have the Commission and the ECDC managed well key activities and resources to support the One Health response of Member States to AMR under the EU Action Plan?
2) Har Kommissionen og EU-agenturerne bidraget effektivt til at fremme forsigtig anvendelse af antimikrobielle stoffer til dyr og reducere antimikrobiel resistens i EU? 
(2) Have the Commission and EU agencies contributed effectively towards promoting the prudent use of antimicrobials in animals and reducing antimicrobial resistance in the EU?
3) Har Kommissionen og agenturerne haft hensigtsmžssige mekanismer til rdighed til at koordinere og evaluere EU's stżtte til AMR-forskning? 
(3) Have the Commission and EU agencies had appropriate mechanisms to coordinate and evaluate EU support to AMR research?
19 For at besvare disse spżrgsml gjorde vi fżlgende: - Vi undersżgte gennemfżrelsen af relevante foranstaltninger finansieret over sundhedsprogrammet for 2014-2020 - Vi undersżgte, hvordan EU's ramme for overvgning af AMR i dyr bestemt til fżdevareproduktion og i fżdevarer samt forbruget af antimikrobielle stoffer til dyr var blevet gennemfżrt siden 2013 - Vi sendte spżrgeskemaer til alle medlemsstaternes nationale koordinatorer af AMR-handlingsplaner med henblik p at f mlrettede oplysninger om deres foranstaltninger og deres syn p den stżtte, de modtog fra Kommissionen og ECDC - Vi hżrte nationale myndigheder og andre myndigheder i Sverige, Nederlandene, Spanien og Frankrig med ansvar for fem af de ni arbejdspakker under JAMRAI, der er mest relevante for vores revision, og med ansvar for visse andre forskningsprojekter. Vi besżgte ogs WHO Europa og OECD 16 
19 To answer these questions, we have: Ń examined the implementation of relevant actions funded from the 2014-2020 Health Programme; Ń examined how the EU framework for AMR monitoring in food-producing animals and food, and for antimicrobial consumption in animals was implemented since 2013; Ń surveyed national AMR Action Plan coordinators in all Member States to obtain targeted information on their actions and their views on the support they received from the Commission and the ECDC; Ń consulted national and other authorities in Sweden, the Netherlands, Spain and France responsible for five of the nine work packages under JAMRAI most relevant for our audit; and for certain research projects.
- Vi undersżgte Kommissionens og agenturernes stżtte til AMR-forskning siden RP7 med fokus p ND4B-programmet. 
We also visited WHO Europe and the OECD; Ń examined the Commission and agenciesŐ support to AMR research since FP7, with a focus on the ND4BB programme.
Dette omfattede en undersżgelse af, hvordan stżttemodtagerne gennemfżrte de finansierede foranstaltninger. 17 
This included examining how beneficiaries implemented funded actions. 15
Bemžrkninger Kommissionens og ECDC's stżtte til medlemsstaternes One Health-tilgang til AMR har endnu ikke leveret pviselige resultater med hensyn til at reducere AMR 20 Kommissionen og ECDC stżtter medlemsstaternes udarbejdelse og gennemfżrelse af de nationale One Health-handlingsplaner vedrżrende AMR, som er omfattet af deres WHO-forpligtelser. 
Observations Commission and ECDC support for Member StatesŐ One Health approach has not yet delivered demonstrable results in reducing AMR 20 The Commission and ECDC support Member States to establish and implement their National One Health Action Plans (NAPs) for AMR, which they agreed to under their WHO commitments.
Denne stżtte har form af ekspertise ydet via teknisk vejledning, fžlles besżg og overvgningsnet samt finansiel stżtte til foranstaltninger under EU's sundhedsprogram. 
This support is in terms of expertise through technical guidance, joint visits and surveillance networks; and through financial support for actions from the EU Health Programme.
Vi undersżgte derfor, om denne stżtte blev forvaltet hensigtsmžssigt og bidrog til bžredygtige resultater i forbindelse med bekžmpelsen af AMR. 
We therefore examined whether this support was well managed and contributed to sustainable results in addressing AMR.
Vi vurderede ogs, om de oplysninger, der var indsamlet via overvgningsnet, var fuldstžndige og relevante. 
We also assessed whether information collected by surveillance networks was complete and relevant. 16
Foranstaltninger finansieret af Kommissionen stżttede bekžmpelsen af AMR, men mżdte udfordringer 21 Kommissionen ydede stżtte ved over sundhedsprogrammet at finansiere relevante aktiviteter vedrżrende den fžlles aktion om antimikrobiel resistens 18 (JAMRAI), WHO og OECD (jf. tabel 1). 
Commission funded actions supported the fight against AMR but faced challenges 21 The Commission provided support through funding relevant activities from the Health Programme for the Joint Action on Antimicrobial Resistance (JAMRAI), the WHO and the OECD (see Table 1).
Den oprettede ogs One Health-netvžrket, vejledte og underviste. 
It also organised the One Health Network, provided guidance and training.
22 Vi indhentede synspunkter gennem en spżrgeundersżgelse henvendt til medlemsstaternes myndigheder med ansvar for nationale handlingsplaner. 
22 We obtained views from a survey of Member State authorities responsible for National Action Plans.
Svarene viste, at kvaliteten af den stżtte og vejledning, som Kommissionen og ECDC ydede, generelt var hżjt vžrdsat. 
These replies showed a general high appreciation of the quality of the support and guidance provided by the Commission - and the ECDC.
To tredjedele af respondenterne var af den opfattelse, at JAMRAI ydede effektiv stżtte, og at den undervisning, som Kommissionen tilbżd vedrżrende One Health-tilgangen, var nyttig. 
Two thirds of respondents considered that JAMRAI provided effective support; and that the training provided by the Commission on the One Health approach was beneficial.
Tre fjerdedele af respondenterne mente, at One Health-nettene var nyttige. 
Three quarters of respondents considered the One Health Networks were useful.
Deres syn p Kommissionens vejledning om forsigtig anvendelse af antimikrobielle stoffer til human og veterinžr brug var ligeledes positivt. 
Their views on the CommissionŐs guidance on the prudent use of antimicrobials, for human and animal use, were similarly positive.
Tabel 1 - Foranstaltninger finansieret over sundhedsprogrammet til stżtte for AMR-politikker 19 Aktion Budget (000 euro) Kortfattet beskrivelse Fžlles aktion om antimikrobiel resistens (JAMRAI) 4 200 JAMRAI16 sigter mod at fremme synergi mellem EU's medlemsstater ved at udvikle og gennemfżre effektive One Health-politikker og reducere antallet af infektioner erhvervet i sundhedsvžsenet. Den har ni arbejdspakker og 19 deltagende medlemsstater og udgżr en platform for udveksling af erfaringer og udvikling af bedste praksis. 
Table 1 Đ Measures funded from the Health Programme to support AMR policies 17 Action Budget (000 euro) Summary description Joint Action on Antimicrobial Resistance (JAMRAI) 4 200 JAMRAI16 aims at fostering synergies between EU Member States by developing and implementing effective One Health policies and reducing Health care associated infections; It has 9 work packages and 19 Member States, and provides a platform for exchange of experiences and developing best practices.
WHO 600 Denne aktion stżtter medlemsstaterne med hensyn til at udvikle og gennemfżre One Health-handlingsplaner. 
WHO 600 This action supports Member States to develop and implement national One Health action plans.
OECD 340 OECD vurderede den żkonomiske byrde ved AMR. 
OECD 340 OECD assessed the economic burden of AMR.
Den beregnede, at aktioner med henblik p at reducere AMR var gode investeringer, der snart ville mere end tjene sig selv ind. 
It calculated that actions to reduce AMR were good investments that would soon more than pay for themselves.
EU JAMRAI vision/opgave. 
16 See EU JAMRAI vision / mission.
Den kommissionsfinansierede fžlles aktion om antimikrobiel resistens (JAMRAI) mżdte udfordringer, men lettede samarbejdet mellem medlemsstaterne 23 JAMRAI startede den 1. september 2017 og vil stržkke sig over 36 mneder. 
The Commission-funded Joint Action on Antimicrobial Resistance (JAMRAI) faced challenges while facilitating cooperation between Member States 23 JAMRAI started on 1 September 2017, and will run for 36 months.
Vi konstaterede, at de fleste af JAMRAI's arbejdspakker17 generelt var p vej til at producere deres aftalte resultater, og at JAMRAI er en god platform for udveksling af erfaringer og bedste praksis mellem de 19 deltagende medlemsstater18. 
We found that most JAMRAI work packages17 were generally on track to produce their agreed deliverables and that JAMRAI provides a good platform for exchanges of experiences and best practices between the 19 participating Member States18.
24 JAMRAI mżdte imidlertid visse udfordringer. 
24 However, JAMRAI faced some challenges.
Den havde ikke en samlet One Health-tilgang, da der ikke var nogen miljżmyndigheder involveret i arbejdspakkerne, og deltagelsen fra medlemsstaternes veterinžrmyndigheder var relativt lav. 
It did not have a complete One Health approach, as there were no environmental authorities involved in Work Packages, and there was a relatively low participation from Member State veterinary authorities.
Arbejdspakke 4 (om integrering i nationale politikker og bžredygtighed) og 7 (om hensigtsmžssig brug af antimikrobielle stoffer til mennesker og dyr) oplevede forsinkelser. 
Work Packages 4 (for integration in national policies and sustainability) and 7 (for the appropriate use of antimicrobials in humans and animals) were experiencing delays.
Envidere vil JAMRAI's samlede succes i hżj grad afhžnge af de foranstaltninger, som medlemsstaterne efterfżlgende tržffer for reelt at gennemfżre de lżsninger, som er udviklet med arbejdspakkerne. 
Furthermore, JAMRAIŐs overall success will depend largely on actions subsequently taken by the Member States to actually implement the solutions developed by the work packages.
WHO-projektet havde ikke stżttet det planlagte antal medlemsstater i sit fżrste driftsr 25 WHO-projektet begyndte i maj 2018 og forventes at kżre i tre r for at hjžlpe medlemsstaterne med at udvikle og gennemfżre nationale One Health-handlingsplaner. 
The WHO project had not supported the targeted numbers of Member States in itsŐ first year of operation 25 The WHO project began in May 2018 and is scheduled to run for three years, to help Member States develop and implement national One Health action plans.
Kommissionen sżrgede for, at WHO fremlagde projektet for medlemsstaterne i EU's Udvalg for Sundhedssikkerhed i juni 2018 og i One Health-netvžrket. 
The Commission arranged for WHO to present the project to Member States in the EU Health Security Committee in June 2018 and in the One Health Network.
Dette projekt var forsinket p tidspunktet for revisionen og havde ikke stżttet det planlagte antal medlemsstater i forbindelse med sine forskellige delml (fire medlemsstater i alt i stedet for 8-12 i forbindelse med hvert delml). 
This project was behind schedule at the time of the audit and had not supported the targeted numbers of Member States for its various sub-objectives (a total of four instead of 812 for each sub-objective).
20 17 De ni arbejdspakker er: 1. koordinering; 2. spredning; 3. evaluering; 4. integrering i nationale politikker og bžredygtighed; 5. gennemfżrelse af nationale One Health-strategier og nationale handlingsplaner for AMR; 6. forebyggelse af infektioner erhvervet i sundhedsvžsenet; 7. hensigtsmžssig brug af antimikrobielle stoffer til mennesker og dyr; 8. oplysningsaktiviteter og kommunikation og 9. prioritering og gennemfżrelse af forskning. 
The Commission funded OECD study on the economic and healthcare burden of AMR was a signpost for targeted and cost-effective action 26 The OECDŐs report19 from 2018 concluded that tackling AMR was a good investment because there was a return in terms of avoided deaths and cost savings for 17 The nine work packages are: 1. Coordination; 2. Dissemination; 3.
18 Plus Norge. 
18 Plus Norway.
Den viste, at aktioner til at reducere AMR var relativt billige, omkostningseffektive og gennemfżrlige (jf. tekstboks 2). 
It showed that actions to reduce AMR were relatively cheap, cost-effective and feasible (see Box 2).
21 Tekstboks 2 Konklusionerne i OECD's rapport - en opfordring til handling OECD's rapport fra 2018 "Stemming the superbug tide Đ Just a few dollars more" oplyser, at tre ud af fire dżdsfald som fżlge af superbuginfektioner kan afvžrges ved at bruge bare 2 USD pr. person om ret p foranstaltninger s enkle som fremme af hndvask og mere forsigtig ordinering af antibiotika. 
Box 2 OECD report findings - an invitation for action The 2018 OECD report ŇStemming the superbug tide Đ Just a few dollars moreÓ indicates that three out of four deaths from superbug infections could be averted by spending just $ USD 2 per person a year on measures as simple as facilitating handwashing and more prudent prescription of antibiotics.
Op til 1,6 millioner liv vil kunne reddes frem til 2050 i de 33 lande, som indgik i OECD's analyse, ved at anvende foranstaltninger ssom: fremme af hospitalshygiejne, reduktion vedrżrende overdreven ordinering af antibiotika, forbedring af programmer for antimikrobiel forvaltning, gennemfżrelse af kampagner i massemedierne og anvendelse af hurtige test til at afgżre, om en infektion er bakteriel eller viral. 
Up to 1.6 million lives would be saved by 2050 across the 33 countries included in the OECD analysis, by using measures such as: promoting hospital hygiene; reducing over-prescription of antibiotics; improving antimicrobial stewardship programmes; mass media campaigns; and the use of rapid tests to detect whether an infection is bacterial or viral.
OECD er af den opfattelse, at investeringer i disse foranstaltninger kan tjene sig selv ind inden for et r og give besparelser p ca. 1,5 USD for hver dollar, der investeres efterfżlgende. 
OECD considers that investments in these measures could pay for themselves within one year and produce savings of about $ 1.5 USD for every dollar invested afterwards.
Hvis disse foranstaltninger kombineres p en sammenhžngende mde, vil det kunne give endnu stżrre fordele og besparelser. 
Combining these measures in a coherent way would yield even higher benefits and savings.
27 Vi bemžrker i den forbindelse, at sundhed ikke er en strategisk investeringsprioritet for strukturfondene i den nuvžrende programmeringsperiode, men at strukturfondene anvendes til investeringer i sundhed. 
27 In this context we note that health is not a strategic investment priority for the Structural Funds in the current programming period, but that the Structural Funds are used for the investments in health.
En undersżgelse finansieret af Kommissionen20 konstaterede, at 7 404 sundhedsprojekter blev finansieret af strukturfondene mellem 2014 og 2018 med en samlet tildeling p otte milliarder euro. 
A Commission-funded study20 found that 7 404 health projects were funded by the Structural Funds between 2014-2018, with a total allocation of Ű8 billion.
Kun to af disse blev identificeret som projekter med specifikke AMR-ml. 
Only two of these projects were identified as having specific AMR objectives.
I undersżgelsen blev det konstateret, at den ptžnkte inklusion af EU's 19 "Stemming the superbug tide - Just a few dollars more", OECD, 2018. 
The study identified that the intended inclusion of the EU Health Programme in the Structural Funds under ESF+ was an opportunity to achieve further synergies between funding instruments and investments in cross-sectoral collaboration21.
20 ESI Funds for Health - Investing for a healthy and inclusive EU - Final Report, Milieu Law and Policy Consulting, 2019. 
20 ESI Funds for Health Đ Investing for a healthy and inclusive EU Đ Final Report, Milieu Law and Policy Consulting, 2019.
ECDC's aktioner leverede vžrdifuld stżtte til Kommissionen og medlemsstaterne i bekžmpelsen af AMR 28 ECDC udfżrer en ržkke AMR-relaterede opgaver. 
ECDC actions provided valuable support to the Commission and Member States in fighting AMR 28 The ECDC performs a range of AMR related tasks.
Det koordinerer overvgningen af AMR, af forbruget af antimikrobielle stoffer og af infektioner erhvervet i sundhedsvžsenet med tre netvžrk: det europžiske overvgningsnet for antimikrobiel resistens (EARS-Net), det europžiske net til overvgning af forbruget af antimikrobielle stoffer (ESAC-Net) og overvgningsnettet for infektioner erhvervet i sundhedsvžsenet (HAI-Net) under programmet for AMR og infektioner erhvervet i sundhedsvžsenet (ARHAI) Disse overvgningsnet leverer vigtige videnskabelige oplysninger i et harmoniseret format, som anvendes til ECDC's videnskabelige rdgivning, uddannelse, landebesżg og oplysningsaktiviteter. 
It coordinates surveillance of AMR, antimicrobial consumption and healthcare-associated infections with three networks, i.e. the European Antimicrobial Resistance Surveillance Network (EARS-Net); the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) and the Healthcare-Associated Infections surveillance Network (HAI-Net), under the AMR and Healthcare-Associated Infections (ARHAI) programme. These surveillance networks provide key scientific information in a harmonised format, which is used for ECDCŐs scientific advice, training, country visits and awareness raising activities.
ECDC bruger oplysninger fra disse net til p vegne af EU-/EŻS-lande at levere data til WHO. 
The ECDC uses information from these networks to contribute data, on behalf of EU / EEA countries to the WHO.
29 EDCD gennemfżrer landebesżg med det forml at yde bistand til nationale myndigheder. 
29 ECDC performs country visits aimed at providing assistance to national authorities.
Mellem 2006 og 2017 gennemfżrte ECDC 25 sdanne besżg med sžrlig vžgt p anvendelsen af antimikrobielle agenser i humanmedicin. 
Between 2006 and 2017, ECDC conducted 25 such visits devoted to the use of antimicrobial agents in human medicine.
Siden lanceringen af EU's One Health-handlingsplan i 2017 gennemfżrer ECDC og Kommissionen fžlles landebesżg som led i en One Health-tilgang, som kombinerer menneskers og dyrs sundhed. 
Since the launch of the EU One Health Action Plan in 2017, ECDC and the Commission perform joint country visits in a One Health approach, combining human and animal health.
Besżg gennemfżres efter invitation fra en medlemsstat. 
These are performed upon invitation from a Member State.
I april 2019 var der gennemfżrt seks sdanne besżg (den oprindelige plan var at gennemfżre seks besżg pr. r), idet de fleste medlemsstater ikke har anmodet om dem. 
By April 2019 there had been six such visits (compared with an initial plan to do six per year), as most Member State have not requested them.
Svarene p vores spżrgeundersżgelse indikerede, at disse besżg havde en betydelig indvirkning p udviklingen af de pgžldende medlemsstaters AMR-foranstaltninger. 
The replies to our survey indicated that these visits had a significant impact on the development of AMR actions by the Member States concerned.
30 Vi bemžrkede, at ECDC modtog et stigende antal AMR-relaterede anmodninger om bistand. 
30 We noted that ECDC received an increasing number of AMR-related requests for assistance.
Det udsatte aktiviteter, nr vigtigere anmodninger havde prioritet. 
It postponed activities when more important requests took priority.
Vi er af den opfattelse, at ECDC's aktiviteter oplyser bde Kommissionen og medlemsstaterne, men noterer os, at der er en stigende risiko for, at ECDC ikke kan udfżre vigtigt AMR-arbejde til tiden. 
We consider that ECDCŐs activities inform both the Commission and Member States, while noting the increasing risk that ECDC cannot perform important AMR work on time.
Der var mangler i oplysningerne om AMR-resultater og -overvgning 31 Kommissionens overordnede ml er at gżre EU til forbillede for bedste praksis for s vidt angr AMR og forbrug af antimikrobielle stoffer. 
There were gaps in information on outcomes and surveillance of AMR 31 The CommissionŐs overall objective is to make the EU a best practice region for AMR and antimicrobial consumption.
I forbindelse med sin EU-handlingsplan anmodede den derfor EU-agenturerne (ECDC, EFSA og EMA) om at udarbejde en videnskabelig udtalelse om resultatindikatorer for One Health-handlingsplanen, som kunne anvende de eksisterende overvgningsdata. 
In the context of its EU action plan, it thus requested the EU agencies (ECDC, EFSA and EMA) to produce a scientific opinion on outcome indicators for AMR One Health Action that could use existing surveillance data.
Disse indikatorer bżr hjžlpe medlemsstaterne med overvgningen af deres fremskridt med at reducere anvendelsen af antimikrobielle stoffer og bekžmpe AMR hos mennesker og dyr bestemt til fżdevareproduktion og med at fastlžgge ml for mindskelse af risikoen for AMR. 
Those indicators should assist Member States in monitoring their progress in reducing the use of antimicrobials and AMR in humans and food-producing animals, and to set targets to decrease risks of AMR. 20
32 Som fżlge af denne anmodning udarbejdede agenturerne en fžlles videnskabelig udtalelse om resultatindikatorer i oktober 201722. 
32 Following this request, the agencies produced a Joint Scientific Opinion on outcome indicators in October 201722.
Vi konstaterede p tidspunktet for revisionen (april 2019), at status for disse resultatindikatorer var usikker, og at hverken de medlemsstater, vi besżgte, eller Kommissionen brugte dem konsekvent til at overvge fremskridt. 
At the time of the audit (April 2019), we found that the status of these outcome indicators was uncertain, and that they were not consistently used by the Member States we visited, or by the Commission, to monitor progress.
Overvgningen af infektioner erhvervet i sundhedsvžsenet var ufuldstžndig p trods af EU's retlige krav 33 Der er samstemmende beviser for23, at infektioner erhvervet i sundhedsvžsenet er den vigtigste kilde til AMR-infektioner hos mennesker i Europa. 
Surveillance of healthcare associated infections was incomplete despite EU legal requirements 33 There is consistent evidence23 that healthcare associated infections (HAIs) are the primary source of infection by AMR in humans in Europe.